Levemir (Insulin Detemir)
insulin detemir
Novo Nordisk has announced the global discontinuation of Levemir (insulin detemir). In the United States, production was phased out beginning in late 2024. Globally, remaining supplies are expected to be exhausted by December 2026. Clinicians should not initiate new patients on insulin detemir and should plan to transition existing patients to alternative basal insulins such as insulin glargine (Lantus, Basaglar, Toujeo), insulin degludec (Tresiba), or insulin icodec (Awiqli). This monograph is retained as a clinical reference for patients still on existing supply.
Indications for Insulin Detemir
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Type 1 diabetes mellitus | Adults and pediatric patients ≥2 years | Basal component of basal-bolus regimen (must use with rapid-acting mealtime insulin) | FDA Approved |
| Type 2 diabetes mellitus | Adults | Monotherapy or adjunctive with oral antidiabetic agents, GLP-1 RAs, or mealtime insulin | FDA Approved |
Insulin detemir received initial FDA approval in June 2005 as a long-acting basal insulin analog for glycemic control in patients with type 1 and type 2 diabetes. In type 1 diabetes, it must always be used alongside rapid-acting mealtime insulin, as it provides basal coverage only. In type 2 diabetes, it may serve as standalone basal therapy or in combination with oral agents, GLP-1 receptor agonists, or bolus insulin. It is not recommended for the treatment of diabetic ketoacidosis. Notably, the pediatric indication covers children aged 2 years and older with type 1 diabetes only (FDA PI).
Pregnancy (type 1 diabetes): A randomized trial of 310 pregnant women with type 1 diabetes demonstrated similar pregnancy outcomes and fetal safety compared with NPH insulin. Insulin detemir is used off-label in pregnancy when clinicians judge the benefit outweighs potential risk. Evidence quality: Moderate.
Pediatric type 2 diabetes: Although the FDA indication specifies adults for T2DM, insulin detemir has been used off-label in adolescents with type 2 diabetes requiring basal insulin. Evidence quality: Low.
Dosing of Insulin Detemir
Adult Dosing by Clinical Scenario
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| T2DM — insulin-naïve, basal-only initiation | 10 units once daily in evening or 0.1–0.2 units/kg/day | Titrate individually | No fixed ceiling | May be given once daily (evening/bedtime) or divided BID If once daily inadequate, consider splitting to twice daily |
| T2DM — switching from NPH insulin | Same total daily basal unit dose | Titrate to target | No fixed ceiling | Unit-for-unit from NPH; however, some T2DM patients may need MORE detemir than NPH In one trial, mean end-of-treatment dose was 0.77 U/kg (detemir) vs 0.52 U/kg (NPH) |
| T2DM — switching from insulin glargine | Same total daily basal unit dose | Titrate to target | No fixed ceiling | Unit-for-unit conversion Consider twice-daily dosing if switching from once-daily glargine and glycemic control was suboptimal |
| T1DM — insulin-naïve | ⅓ to ½ of total daily insulin dose Total daily dose: 0.2–0.4 units/kg/day | Titrate to fasting glucose target | No fixed ceiling | Remainder as rapid-acting insulin divided across meals Must always use with mealtime insulin in T1DM |
| T1DM — basal-bolus, twice-daily regimen | Split basal dose: morning + evening (12 h apart) | Titrate each dose independently | No fixed ceiling | Twice-daily dosing often preferred in T1DM for more consistent 24-h coverage Evening dose given at dinner or bedtime |
Pediatric Dosing (≥2 Years, Type 1 Diabetes)
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| T1DM — new to insulin | ⅓ to ½ of total daily insulin dose | Titrate individually | No fixed ceiling | Once or twice daily; usual maintenance ≤1.2 units/kg/day during growth spurts Supported by Studies D and I in 694 patients aged 2–17 years |
| T1DM — switching from NPH insulin | Same total daily basal unit dose | Titrate to target | No fixed ceiling | Unit-for-unit conversion Monitor closely during transition; adjust bolus insulin as needed |
Unlike insulin degludec (half-life ~25 h), insulin detemir has a relatively short terminal half-life of 5–7 hours, meaning its duration of action is dose-dependent and may not reliably cover a full 24-hour period in all patients. In clinical trials, once-daily dosing was most effective in T2DM patients receiving lower doses, whereas many T1DM patients and T2DM patients requiring higher doses benefited from twice-daily administration (every 12 hours) for more consistent basal coverage. If a patient on once-daily detemir experiences rising pre-dinner glucose or overnight hyperglycemia, consider splitting the dose (FDA PI).
Pharmacology of Insulin Detemir
Mechanism of Action
Insulin detemir is a recombinant human insulin analog produced in Saccharomyces cerevisiae. Its molecular structure differs from endogenous human insulin by the deletion of threonine at position B30 and the attachment of a 14-carbon myristic acid fatty acid chain to lysine at position B29. This acylation enables two key protraction mechanisms: strong self-association of hexamers at the subcutaneous injection site (slowing systemic absorption) and reversible binding to circulating albumin (>98%), which slows distribution to peripheral target tissues. Once free insulin detemir monomers dissociate from albumin, they bind to insulin receptors on skeletal muscle and adipose tissue, activating the insulin signaling cascade to promote glucose uptake, stimulate glycogen synthesis, and suppress hepatic glucose production. The pharmacodynamic profile is relatively flat with no pronounced peak, and the duration of action ranges from approximately 5.7 to 23.2 hours depending on dose (FDA PI).
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Slow SC absorption via self-association; Tmax 6–8 h; absolute bioavailability ~60%; >50% of max effect from 3–4 h to ~14 h | Lower bioavailability than other insulin analogs due to SC depot self-association; dose-dependent duration supports once- or twice-daily dosing |
| Distribution | Vd ~0.1 L/kg; >98% albumin-bound in plasma | Small Vd reflects high albumin binding; albumin binding slows delivery to peripheral tissues and contributes to protracted action profile |
| Metabolism | Degraded similarly to human insulin; no CYP involvement | No hepatic drug-drug interactions via enzyme pathways; safe in hepatic impairment with glucose monitoring |
| Elimination | t½ 5–7 h (terminal, dose-dependent); duration of action up to 24 h | Shorter half-life than glargine (~12 h) and degludec (~25 h); may require twice-daily dosing for reliable 24-h coverage. Elderly patients show up to 35% higher AUC due to reduced clearance. |
Side Effects of Insulin Detemir
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Upper respiratory tract infection | Up to 35% | Most common non-hypoglycemic adverse event; includes common cold symptoms; not considered causally related to insulin therapy |
| Pharyngitis | Up to 17% | Background infection rate; consistent across insulin and comparator arms in clinical trials |
| Headache | ≥5% | One of the two most commonly reported non-hypoglycemic adverse reactions alongside nasopharyngitis across clinical trials (FDA PI) |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Injection site reactions | 3–5% | More frequent with insulin detemir than with NPH insulin; includes pain, redness, swelling, itching; usually minor and transitory |
| Influenza-like illness | ~7% | Background rate; not considered specifically drug-related |
| Weight gain | 1–5% | Notably less weight gain than NPH or glargine; weight gain ranged from 0.5 to 1.2 kg across trials; T1DM patients showed minimal change or slight weight loss |
| Bronchitis | 3–5% | Background respiratory infection rate in trial populations |
| Lipodystrophy | 1–2% | Lipohypertrophy at injection sites; prevented by consistent site rotation |
| Pruritus / Rash | 1–3% | May be localized or generalized; evaluate for allergy if persistent |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Severe hypoglycemia | ~6% (third-party assistance required) | Any time; often nocturnal or pre-meal | Immediate oral glucose or glucagon; assess precipitating factors; adjust dose |
| Anaphylaxis / severe allergic reaction | Rare | Minutes to hours after injection | Emergency treatment; permanent discontinuation of insulin detemir |
| Hypokalemia | Uncommon | Hours after large doses or with potassium-lowering drugs | Monitor potassium in at-risk patients; supplement as needed |
| Heart failure exacerbation (with TZDs) | Uncommon | Weeks to months | Monitor for fluid retention; reduce or discontinue TZD if signs develop |
| Localized cutaneous amyloidosis | Rare (post-marketing) | Months to years with repeated injections at same site | Change injection site; do not inject into affected areas; erratic absorption may result |
| Reason for Discontinuation | Incidence | Context |
|---|---|---|
| Adverse events (any) | <5% | Comparable to NPH insulin across pivotal trials |
| Hypoglycemia | <1% | Rarely necessitates permanent discontinuation |
| Injection site reactions | 0.25% | Three patients reported injection site pain leading to discontinuation across clinical program |
A notable clinical differentiator for insulin detemir compared with other basal insulins has been its weight-neutral to weight-sparing profile. In multiple clinical trials, patients on insulin detemir gained significantly less weight than those on NPH insulin or insulin glargine. In T1DM studies, some patients experienced slight weight loss. This property has been attributed to a central nervous system-mediated reduction in energy intake, possibly related to detemir’s albumin binding and its ability to cross the blood-brain barrier.
Drug Interactions with Insulin Detemir
Insulin detemir is not metabolized by cytochrome P450 enzymes. Although >98% albumin-bound, in vitro studies show no clinically relevant displacement interactions with protein-bound drugs. Drug interactions are primarily pharmacodynamic, involving agents that alter glucose metabolism or mask hypoglycemia warning signs.
Monitoring for Insulin Detemir
-
Blood Glucose
Daily (fasting) during titration; per ADA targets at maintenance
Routine Fasting blood glucose is the primary titration target. Increase frequency during illness, dose changes, or insulin switching. CGM recommended when available. -
HbA1c
Every 3 months until stable, then every 6 months
Routine Individualized targets per ADA 2025 Standards of Care. Consider more frequent testing with regimen changes. -
Potassium
Baseline; periodically in at-risk patients
Trigger-based All insulins drive potassium intracellularly. Monitor in patients on diuretics, digoxin, or other potassium-lowering agents. -
Renal Function
Baseline, then annually
Routine Insulin requirements often decrease in advancing CKD due to reduced renal clearance and diminished counter-regulatory responses. Dose reduction may be necessary. -
Hepatic Function
Baseline; as clinically indicated
Trigger-based Diminished hepatic gluconeogenesis capacity may increase hypoglycemia risk. Monitor glucose more closely in hepatic impairment. -
Injection Sites
Every visit
Routine Inspect for lipodystrophy and cutaneous amyloidosis. Mild injection site reactions occur more frequently with detemir than NPH; most resolve within days to weeks. -
Weight
Every visit
Routine Insulin detemir is associated with less weight gain than other basal insulins. Track trends and reinforce lifestyle measures. -
Hypoglycemia Episodes
Every visit; patient diary or CGM review
Routine Assess frequency, severity, and timing. In T1DM trials, insulin detemir showed slightly fewer episodes of nocturnal hypoglycemia compared with NPH insulin.
Contraindications & Cautions for Insulin Detemir
Absolute Contraindications
- During episodes of hypoglycemia — do not administer while blood glucose is below normal range.
- Hypersensitivity to insulin detemir or any excipient (zinc, m-cresol, glycerol, phenol, disodium phosphate, sodium chloride) — severe anaphylaxis has been reported.
Relative Contraindications (Specialist Input Recommended)
- Diabetic ketoacidosis (DKA) — insulin detemir is not recommended for DKA treatment. Use IV rapid-acting insulin.
- Insulin pump use — insulin detemir must NOT be used in insulin infusion pumps. Its protracted action depends on subcutaneous depot formation.
- Significant heart failure (NYHA Class III–IV) with TZDs — combination increases fluid retention and heart failure risk.
Use with Caution
- Renal impairment — insulin requirements may decrease; increase monitoring frequency.
- Hepatic impairment — reduced gluconeogenic reserve; increase monitoring frequency.
- Elderly patients (≥65 years) — up to 35% higher AUC observed due to reduced clearance. Careful titration and conservative glucose targets recommended.
- IV or IM administration — never administer intravenously or intramuscularly. IV administration of a SC dose could cause severe hypoglycemia. IM absorption is faster and more extensive than SC.
- Visual impairment — patients relying on audible clicks for dose selection should use the FlexTouch pen with caution.
Accidental mix-ups between insulin products have been reported. Patients must always verify the insulin label before each injection. Do not dilute or mix insulin detemir with any other insulin or solution. Never share a FlexPen, FlexTouch, insulin syringe, or needle between patients, even if the needle is changed, due to the risk of transmitting blood-borne pathogens (FDA PI).
Patient Counselling for Insulin Detemir
Purpose of Therapy
Insulin detemir is a long-acting basal insulin that works steadily in the background to help control blood sugar between meals and overnight. In type 1 diabetes, it is always used together with a rapid-acting mealtime insulin. In type 2 diabetes, it may be used alone or alongside other diabetes medications. It does not replace healthy eating, regular exercise, and blood glucose monitoring.
How to Take
Inject insulin detemir under the skin of the thigh, upper arm, or abdomen. Rotate the injection site each time. If used once daily, inject at the evening meal or at bedtime. If used twice daily, space doses approximately 12 hours apart. The solution should appear clear and colorless — do not use if cloudy or discolored. Never mix insulin detemir with other insulins, and never use it in an insulin pump. Store unopened pens and vials in the refrigerator; once in use, store at room temperature (below 30°C / 86°F) for up to 42 days.
Sources
- Novo Nordisk. Levemir (insulin detemir) injection, for subcutaneous use. Full Prescribing Information. Plainsboro, NJ; Revised 2019. FDA Label (PDF) Primary regulatory reference for all dosing, indications, contraindications, adverse effects, and pharmacokinetic data.
- Novo Nordisk. Levemir (insulin detemir) injection prescribing information. DailyMed/NLM. DailyMed Label NLM-hosted version of the most current labeling including patient information and instructions for use.
- Hermansen K, Davies M, Derezinski T, et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naïve people with type 2 diabetes. Diabetes Care. 2006;29(6):1269-1274. doi:10.2337/dc05-1965 Pivotal trial demonstrating non-inferior HbA1c reduction with less weight gain and reduced nocturnal hypoglycemia compared with NPH insulin in T2DM.
- Mathiesen ER, Hod M, Ivanisevic M, et al. Maternal efficacy and safety outcomes in a randomized, controlled trial comparing insulin detemir with NPH insulin in 310 pregnant women with type 1 diabetes. Diabetes Care. 2012;35(10):2012-2017. doi:10.2337/dc11-2264 Key pregnancy safety trial (n=310) supporting the use of insulin detemir in pregnant women with T1DM, showing comparable outcomes to NPH insulin.
- Danne T, Lüpke K, Walte K, et al. Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetes. Diabetes Care. 2003;26(11):3087-3092. doi:10.2337/diacare.26.11.3087 Pharmacokinetic study establishing consistent PK profile across pediatric and adult populations supporting pediatric dosing.
- Rosenstock J, Davies M, Home PD, et al. A randomized, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naïve people with type 2 diabetes. Diabetologia. 2008;51(3):408-416. doi:10.1007/s00125-007-0911-x Head-to-head comparison with insulin glargine in T2DM showing non-inferior HbA1c reduction with significantly less weight gain for detemir.
- American Diabetes Association Professional Practice Committee. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025. Diabetes Care. 2025;48(Suppl 1):S181-S206. doi:10.2337/dc25-S009 Current ADA guidelines for basal insulin selection, titration, and positioning of long-acting insulin analogs in treatment algorithms.
- Newland-Jones P, Beba H, Kanumilli N, et al. Discontinuation of Levemir (insulin detemir): Joint guidance from ABCD and PCDO Society. 2025. ABCD Guidance Multidisciplinary clinical guideline addressing safe switching from insulin detemir to alternative basal insulins following discontinuation announcement.
- Kurtzhals P, Havelund S, Jonassen I, et al. Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo. Biochem J. 1995;312(Pt 3):725-731. doi:10.1042/bj3120725 Foundational study characterizing the fatty acid acylation and albumin binding that underpins detemir’s protracted pharmacokinetic profile.
- Russell-Jones D, Khan R. Insulin-associated weight gain in diabetes — causes, effects, and coping strategies. Diabetes Obes Metab. 2007;9(6):799-812. doi:10.1111/j.1463-1326.2006.00686.x Review discussing the weight-sparing mechanism of insulin detemir, including its hypothesized CNS-mediated appetite suppression effect.
- Plank J, Bodenlenz M, Sinner F, et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care. 2005;28(5):1107-1112. doi:10.2337/diacare.28.5.1107 Dose-response clamp study establishing the dose-dependent half-life (5–7 h), duration of action, and flat pharmacodynamic profile of insulin detemir.
- Heise T, Nosek L, Rønn BB, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes. 2004;53(6):1614-1620. doi:10.2337/diabetes.53.6.1614 Clamp study demonstrating lower within-subject pharmacodynamic variability for insulin detemir versus NPH and insulin glargine in T1DM patients.
- Pieber TR, Treichel HC, Hompesch B, et al. Comparison of insulin detemir and insulin glargine in subjects with type 1 diabetes using intensive insulin therapy. Diabet Med. 2007;24(6):635-642. doi:10.1111/j.1464-5491.2007.02113.x Comparative study of detemir vs glargine in basal-bolus T1DM showing similar efficacy with less weight gain for detemir.